Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Two of the top preforming pieces of content in October was the FDA clearance for the first indication for shortened DAPT for Medtronic's Resolute Onyx Drug Eluting Stent. A virtual tour of the new robotic electrophysiology lab at Banner Health led by Pete Weiss, M.D., also was among the most popular cardiology technology content.
Feature

November 2, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home November 02, 2020
Home
Angiography with a co-registered view of pressure drops according iFR readings in a coronary vessel. The DEFINE PCI study showed patients had improved outcomes and less recurrent chest pain at one year using iFR physiologic measurements combined with landmarks shown on angiographic imaging to better guide therapy. Image by Philips Healthcare. #TCT #TCT2020 #TCTconnect
Feature | FFR Technologies | Dave Fornell, Editor

Fractional flow reserve (FFR) is considered the gold standard measure whether a coronary lesions needs a percutaneous ...

Home October 30, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe.
Feature | Magnetic Resonance Imaging (MRI)

October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a very ...

Home October 29, 2020
Home
News | Atrial Fibrillation

Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the ...

Home October 29, 2020
Home
News | Pulmonary Embolism

October 23, 2020 —  Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world p ...

Home October 23, 2020
Home
News | FFR Technologies

October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided ...

Home October 23, 2020
Home
News | FFR Technologies | Dave Fornell, Editor

October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from ...

Home October 22, 2020
Home
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS  study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect
Feature | Stents | Dave Fornell, Editor

October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable ...

Home October 22, 2020
Home
News | Stents

October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology ...

Home October 22, 2020
Home
Videos | Cath Lab

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
Videos | Stents Drug Eluting

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Subscribe Now